Cargando…
Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease that is prevalent in individuals >50 years of age, with a median survival of 3–5 years and limited therapeutic options. The disease is characterized by collagen deposition and remodeling of the lung parenchyma in a process tha...
Autores principales: | Griffiths, K., Habiel, D. M., Jaffar, J., Binder, U., Darby, W. G., Hosking, C. G., Skerra, A., Westall, G. P., Hogaboam, C. M., Foley, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816662/ https://www.ncbi.nlm.nih.gov/pubmed/29453386 http://dx.doi.org/10.1038/s41598-018-20811-5 |
Ejemplares similares
-
Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4
por: Griffiths, Katherine, et al.
Publicado: (2019) -
A single-domain i-body, AD-114, attenuates renal fibrosis through blockade of CXCR4
por: Cao, Qinghua, et al.
Publicado: (2022) -
CXCR4(+) cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis
por: Jaffar, Jade, et al.
Publicado: (2020) -
Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014) -
Characterization of CD28(null) T cells in Idiopathic Pulmonary Fibrosis
por: Habiel, David M, et al.
Publicado: (2018)